EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF)
recurrences within the first 8 weeks after electrical cardioversion of persistent AF.